<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557427</url>
  </required_header>
  <id_info>
    <org_study_id>REM-1/MDA</org_study_id>
    <secondary_id>REM-1/MDA</secondary_id>
    <nct_id>NCT00557427</nct_id>
  </id_info>
  <brief_title>Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression</brief_title>
  <official_title>Open-labeled Randomized Comparative Study of the Efficacy and Tolerability of Two Times Daily 250mg Hypericum Versus Once Daily 20 - 40 mg Fluoxetine in Adolescent Patients With Mild to Moderate Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rafa Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rafa Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a pilot study where adolescents 12 - 18 years of age with mild to moderate
      depression will be randomized to receive either hypericum 250mg twice daily or fluoxetine
      10mg daily increased to 20mg daily after 1 week and the option to increase to 40mg daily
      after 4 weeks. Patients will be treated for a total of 8 weeks. Efficacy will be measured
      using the CDRS-R, BDI-II and the CGI scales. Safety parameters include blood tests,
      urinalysis and ECG.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinical response (defined by CDRS-R &lt; 28) at the final/withdrawal visit</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a decrease of CDRS-R score &gt; 30 points from baseline</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final mean CDRS-R score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDRS-R score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical response</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypericum 250mg tablets twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluoxetine 20mg - 40mg daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypericum</intervention_name>
    <description>250mg tablets twice daily for 8 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Remotiv</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluoxetine</intervention_name>
    <description>20mg - 40mg daily for 8 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Adolescents aged 12 to 18 years

          -  Patients meeting the criteria for mild to moderate depression according to the DSM-IV
             scale

          -  Physical and laboratory examination at baseline compatible with study criteria

          -  ECG at baseline compatible with study criteria

          -  Score of at least 40 on the Children's Depression Rating Scale - Revised (CDRS-R) at
             baseline

        Exclusion Criteria:

          -  Patients with psychosis, bi-polar disease, schizophrenia or significant developmental
             disorder

          -  Patients with epilepsy

          -  Patients with a history of alcohol or substance abuse in the past year

          -  Initiation of psychotherapy or behavioral therapy in the 2 months prior to screening
             or during the study.

          -  Patients who have previously failed to respond to SSRI's or SRNI's

          -  Patients who have been treated with antidepressants within 2 weeks of screening (4
             weeks if fluoxetine)

          -  Patients with a contraindication to taking either Remotiv or fluoxetine or taking
             medication contraindicated when taking Remotiv or fluoxetine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Apter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, child and adolescent division, Schneider Children's Hospital of Israel, Chairman Dept. of Psychiatry Sackler School of Medicine, Tel-Aviv University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Findling RL, McNamara NK, O'Riordan MA, Reed MD, Demeter CA, Branicky LA, Blumer JL. An open-label pilot study of St. John's wort in juvenile depression. J Am Acad Child Adolesc Psychiatry. 2003 Aug;42(8):908-14.</citation>
    <PMID>12874492</PMID>
  </results_reference>
  <results_reference>
    <citation>Simeon J, Nixon MK, Milin R, Jovanovic R, Walker S. Open-label pilot study of St. John's wort in adolescent depression. J Child Adolesc Psychopharmacol. 2005 Apr;15(2):293-301.</citation>
    <PMID>15910213</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Roy L. Mellovitz</name_title>
    <organization>Rafa Laboratories Ltd.</organization>
  </responsible_party>
  <keyword>mild to moderate depression according to the DSM-IV scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

